Clinical Scientist
Spyre Therapeutics
Clinical Scientist
Spyre Therapeutics
Clinical-stage biotech antibodies for IBD
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
Role Summary:
As a Clinical Scientist at Spyre Therapeutics, you will play a key role in designing, executing, and interpreting clinical trials that support development of our novel antibody-based therapies. You will collaborate across functions (clinical operations, regulatory, translational science, biomarker teams) to ensure robust study designs, high-quality data generation and efficient progression of programs. You will bring scientific and operational expertise and act as a bridge between internal teams, external investigators and CRO partners. You will ensure the integrity, safety, and scientific validity of data collected during clinical studies.
Key Responsibilities:
Ideal Candidate:
What We Offer:
The expected salary range offer for this role is $175,000 to $205,000. Actual pay offered may vary depending on job related knowledge, experience, education, and geographic location.
As an equal opportunity employer, Spyre is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job-related characteristics or other prohibited grounds specified in applicable federal, state and local laws. We also embrace differences in experience and background, and welcome diversity of opinions and thought with active recruitment designed to create a stronger and better Spyre that is focused on developing life-changing products for patients.
Spyre Therapeutics, along with other biotech companies, has become aware of a surge in email scams targeting prospective job candidates within our industry. Please be aware that official recruiters at Spyre Therapeutics only use email addresses with the domain “@spyre.com.” We want to also emphasize that we never request candidates to make any purchases or divulge sensitive personal information via email.
Please also be aware that all job postings will be listed on our website at spyre.com/careers/.
Clinical-stage biotech antibodies for IBD
Spyre Therapeutics develops long-acting antibody therapies for inflammatory bowel disease (IBD), targeting ulcerative colitis and Crohn’s disease with programs such as anti-α4β7 and anti-TL1A. These antibodies are designed to inhibit immune pathways in the gut to reduce inflammation and are built for durable effects, aiming for patient-friendly dosing and potential combo-therapy use. Unlike some peers, Spyre focuses on best-in-class antibodies with durability and a diversified pipeline, shifting away from its past enzyme programs toward immunology-driven treatments for large GI markets. The company aims to discover, develop, and potentially commercialize antibody therapies that address unmet needs in IBD and improve long-term patient outcomes.
Explore more opportunities at Spyre Therapeutics